Biohaven Ltd. (BHVN)
NYSE NYSE Primary Summary
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels
Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash position, reduces R&D costs, and extends the funding runway, addressing prior liquidity concerns. I am upgrading BHVN to Buy, citing promising degrader pipeline assets targeting large autoimmune markets and pivotal trial initiations.
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
Biohaven: Despite Today's Gains, I Remain Skeptical
Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on its degrader programs. BHVN - spun out of the original Biohaven after its acquisition by Pfizer - also has degrader assets focused on autoimmune diseases. Furthermore, there is a Parkinson's program and Obesity program, and some notable catalysts are arriving this year, e.g., pivotal epilepsy topline data.
Biohaven Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 37 | $1,284 | $499.5 | -$784.5 | -61.1% |
 Madelyn D. Purcell Pfizer Inc | 505,645 | $18.89M | $7.28M | -$11.61M | -61.47% |
 Curtis Ellergodt Rothschild Investment LLC | 352 | $7,027.62 | $4,840 | -$2,187.62 | -31.13% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,000 | $8,460 | $14,490 | $6,030 | 71.28% |
| NA Nizar Araji National Bank Of Canada /FI/ | 201 | $1,745.59 | $2,948.67 | $1,203.08 | 68.92% |
Biohaven Ltd. (BHVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biohaven Ltd. ever had a stock split?
Biohaven Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Vladimir Coric CEO | NYSE Exchange | G1110E107 CUSIP |
| US Country | 274 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Biohaven Ltd. is a biopharmaceutical company engaged in discovering, developing, and commercializing treatments across three major areas: immunology, neuroscience, and oncology. With a global presence, Biohaven is committed to advancing a diverse pipeline of promising therapeutic candidates meant to address complex diseases with significant unmet medical needs. The company's comprehensive approach spans a wide range of conditions, from neurological and neuropsychiatric disorders to autoimmune diseases and cancer. Biohaven, initially known as Biohaven Research Ltd., underwent a rebranding to Biohaven Ltd. in September 2022, marking a new phase in its corporate evolution. Additionally, it has a history as a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. and was established in New Haven, Connecticut, in 2022. Biohaven's strategic collaborations with leading academic institutions and industry partners, including Yale University, AstraZeneca, and Katholieke Universiteit Leuven, underscore its commitment to innovation and the translation of scientific research into clinically meaningful therapeutics.
Products and Services
Biohaven Ltd. is focused on developing a broad portfolio of innovative treatments in various stages of clinical development:
- Troriluzole - Currently in Phase 3 clinical trials, Troriluzole is designed for treating neurological and neuropsychiatric illnesses by modulating glutamate levels, offering hope for conditions such as Alzheimer's disease and anxiety disorders.
- BHV-5500 - Targets post-synaptic NMDA receptors to inhibit glutamate signaling. This product is being explored for its potential role in neurological disorders where glutamate plays a key role.
- Taldefgrobep Alfa - In Phase 3 clinical trials, Taldefgrobep Alfa shows promise in treating spinal muscular atrophy and obesity, addressing major gaps in current therapeutic options.
- BHV-7000 - This candidate is in Phase 2/3 clinical trials, aiming to treat a range of conditions, including focal and generalized epilepsy, bipolar disorder, and major depressive disorder, through mechanisms that remain under exploration.
- BHV-2100 - Still in the early Phase 1 clinical trials, BHV-2100 is exploring new frontiers in the treatment of migraines and neuropathic pain, conditions affecting millions globally.
- BHV-8000 - Targets early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities, and is in Phase 1 clinical trials. This indicates Biohaven's commitment to tackling neurodegenerative diseases.
- BHV-1300 to BHV-1600 - This range includes candidates in Phase 1 clinical trials for autoimmune and cardiovascular conditions, such as rheumatoid arthritis and dilated cardiomyopathy, showcasing Biohaven's dedication to a diverse set of diseases.
- BHV-1100 & BHV-1500 - Focusing on oncology, these candidates are in early-stage trials for multiple myeloma and Hodgkin's lymphoma, respectively, as well as preclinical stages for targeting carcinomas, bringing new hope to cancer patients.
Through these efforts, Biohaven Ltd. embodies a forward-thinking approach to pharmaceutical development, leveraging cutting-edge science and strategic partnerships to foster innovation and provide new solutions for patients worldwide.
